Virtual Library

Start Your Search

Jui Ying Fu



Author of

  • +

    P2.11 - Screening and Early Detection (ID 178)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Screening and Early Detection
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.11-04 - Longitudinal Surveillance of Circulating Tumor Cell in Patients Who Presented with Resectable Pulmonary Lesion Suspicious Malignancy (ID 659)

      10:15 - 18:15  |  Author(s): Jui Ying Fu

      • Abstract

      Background

      Lung cancer is a leading cause of cancer-related death. The major factor that affect patients’ survival was recurrence and could only detect by image tools. The most crucial disadvantage of image modalities was only detected the space occupying lesions instead of minimal residual disease.   More and more undetermined lung lesions were identified by lung cancer screening and majority were early stage non small cell lung cancer. We need a less invasive tool to help us detecting minimal residual disease in order to improve patients’ survival. The aim of this study was tried to clarify the clinical significance of CTCs for patients with resectable lesion suspect malignancy

      Method

      From January 2017 to December 2018, 51 consecutive patients were enrolled into this study. One patient who could not tolerable tumor resection due to unstable intraoperation saturation was excluded. All patients received tumor resections. CTCs and image survey were check at scheduled time table. Data from medical record were collected and analyzed with CTCs in order to analyze the its clinical significance

      Result

      Median follow-up time of 12.1 (1.5 – 23.6) months, a total of 386 CTC tests were performed in this cohort when the cutoff data was in December 2019. The mean and median number of CTC testing of the whole cohort were both 7.0 cells/mL (range, 4.0-12.0; SD, 2.4). CTC counts declined with statistical significance in all patients. CTC count declined in first 3 days was 2.2637 (cells/ ml/ day) which was statistically significant in cancer group. (P = 0.0009) The daily decline of CTC counts in lung cancer without recurrence (n=30) was 2.5359 (cells/mL/day) within the first 3 days of surgery and 1.4 (cells/mL/day) in lung cancer with recurrence (n=11). For lung cancer without relapse, the daily decline of CTC counts is statistically significant after adjust. ( P=0.0068). The CTC decline in stage I and Tis group (n=26) was 2.8526 cell/ ml/day and remained statistically significant after adjust. (P = 0.0079)

      Conclusion

      CTCs had high detection rate in all clinical scenarios that could be identified in resectable undetermined lung lesions. CTC counts drop the lowest point in post-operation day 1 in all scenarios and rebound in post-operation day 3 for those patients were confirmed with relapse. Greater CTC count declined in first 3 days were identified in patients who presented with benign lesion and non small lung cancer without relapse.